Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
• To assess the safety and tolerability of up to 7 repeated injections of CAD106 with or without adjuvant (Alum or MF59) in patients with mild Alzheimer’s Disease (AD) over 90 weeks. • To compare the immunogenicity of CAD106 with Alum or MF59 in patients with mild Alzheimer’s Disease (AD) as measured by the titers of Aβ-specific IgG in serum across regimens and in reference to non-adjuvanted CAD106.
Critère d'inclusion
- Alzheimer's disease